Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Edouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, Francesca Parisi, Teresa Gorria, Rosario Garcia-Campelo, Naomi Dempsey, David J. Pinato, Roxana Reyes, Victor Albarran-Artahona, Filippo Dall'Olio, Davide Soldato, Lizza Hendriks, Frank Aboubakar Nana, Marion Tonneau, Rafael Lopez-Castro, Ernest Nadal, Suzanne Kazandjian, Thierry Muanza, Felix Blanc-DurandElizabeth Fabre, Natalia Castro, Hugo Arasanz, Adrien Rochand, Benjamin Besse, Bertrand Routy*, Laura Mezquita

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Downloads (Pure)

Abstract

Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 % of the patients were female, 72.6 % had an adenocarcinoma and 43.5 % had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 %) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 %) patients received taxane monotherapy, 25 (20.1 %) taxane plus anti-angiogenic, 12 (9.7 %) platinum-based chemotherapy and 30 (24.2 %) other chemotherapy.
Original languageEnglish
Pages (from-to)116-122
Number of pages7
JournalLung Cancer
Volume178
Issue number1
DOIs
Publication statusPublished - 1 Apr 2023

Keywords

  • Non small cell lung cancer
  • Chemo-immunotherapy
  • Second line
  • Prognosis
  • Survival
  • DOCETAXEL
  • NIVOLUMAB

Fingerprint

Dive into the research topics of 'Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this